Dec 07, 2020 12:54 PM EST
The COVID-19 vaccine would be the answer to end the pandemic. But even if the vaccine distribution starts today, it won't be enough for all people who need it worldwide.
A new antiviral drug, Molnupiravir or MK-4482 / EIDD-2801, can manage to "completely" stop the transmission of the virus within 24 hours, as per the Institute of Biomedical Sciences of Georgia State University studies.
Researchers explained in the published work in the journal Nature Microbiology that it is the first demonstration of an oral drug available to quickly block the transmission of SARS-CoV-2 that would be a game-changer.
According to Entrepreneur, Emory University in Atlanta developed Molnupiravir through an innovation company Drug Innovation Ventures at Emory (DRIVE), licensed by Ridgeback Biotherapeutics, and partnered with Merck & Co. The antiviral drug was initially being made to treat the flu and prevent the coronavirus from duplicating itself and creating errors amid viral RNA replication.
Tests were carried out on ferrets and observed that they reduced the number of viral particles and the experts' details. Then, ferrets were put to others, which had not been treated. In the second group, none of the ferrets became infected with COVID-19.
Dr. Robert Cox, the co-lead author of the study and a postdoctoral fellow in the Plumper group, said, "We believe that ferrets are a relevant transmission model. Because they easily spread SARS-CoV-2, but for the most part they do not develop a serious disease, which is very similar to the spread of SARS-CoV-2 in young adults."
Cox added that they observed early that the antiviral drug has a broad-spectrum activity to fight respiratory RNA viruses. Besides, the oral treatment of infected animals with the Mogul Parivar reduced the number of viral particles spread by different magnitude orders, which reduced the transmission. Monulparivir's properties are a powerful candidate for the pharmacological suppression of COVID-19, the report adds.
COVID-19 patients treated with the antiviral drug could be non-infectious within 24 hours of the initial treatment if the ferret-based data will be translated to humans. Monulparivir can be taken orally, and treatment can start early for a triple potential benefit: shortening the infectious phase to alleviate the emotional, shortening the infectious phase to lessen the emotional and socioeconomic cost of prolonged patient isolation immediately contain local outbreaks.
The antiviral drug is now on an advanced phase II/ III clinical trial and is being tested in three various doses every 12 hours within five days in patients with COVID-19.
Americans are skeptical about the COVID-19 vaccines, with a "warp speed" timeline that blunts confidence and fears political interference in the shots. According to NBC News, two promising vaccines lead the release within weeks; experts in immunization behavior and ethics say they assume attitudes to shift from widespread hesitancy to urgent and heated demand.
Dr. Paul Offit, a vaccinologist with Children's Hospital of Philadelphia, said in a recent JAMA Network webinar, "People talk about the anti-vaccine people being able to kind of squelch uptake. I don't see that happening."
BRG International Founder Matias Alem had recognized this fact for a few years. So he remodeled his real estate brokerage into something completely new to solve the problem for his jet-setting international client base.
Ryan Early, hailed as 'Farmer Ryan' among sustainable agriculture experts, is a busy man. He has a laundry list of companies to his name, including Blue-Green Ventures, the company behind the revolutionary product, Blue MagicTM, a non-toxic and eco-sustainable pest preventative product using his patented BiomeMax TM Pheromonal Replication Technology.
Investor, financier, and expert in both cryptocurrencies and blockchain technology, Joy Mbanugo is the go-to in the sector. She has vast experience and knowledge across tax services, auditing, business operations, financial analysis, capital markets, and other specializations.
When Nick Collins was just 14 years old, he started his first business, which included around-the-clock phone calls and numerous questions from his parents. In fact, he began building his stout portfolio in the seventh grade by doing web design, incorporating creative content with brand strategies and plugging in a then-fledgling tech Flash.
Barry Gabster is the founder of InitiateU and is a leading proponent of the marketing mailer revolution, having already taken his company to 10x growth in 2021, alone. In fact, the exponential growth has seen the company rise from $800K-$8.5M just on word-of-mouth referrals.
If you think that the micro accounts are useful only for beginners who may not be able to cope with the fast dynamics of changing quotes on trading platforms, then this is not so. Professionalism grows out of these cent accounts.
Journalists love their jobs because they get to interact with people from all sorts of backgrounds and expertises, then turn around and share their knowledge with the world.
As the metaverse takes over more of our digital lives, the commoditization of all aspects of our virtual beings becomes more and more of a reality.
Rustam Gilfanov is a famous IT businessman, a founder of a large IT company, and a partner of the LongeVC Fund.